Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for terminal delirium at end of life
ACTRN12618000658213Phase 2Completed
- Sponsor
- Illawarra Shoalhaven Local Health District
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexmedetomidine in delirium, sponsored by Illawarra Shoalhaven Local Health District. Primary endpoint: Change in delirium. Started Nov 2018; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
delirium
Beyond the preview
Go deeper on ACTRN12618000658213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000658213.